Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 57%
Buy 36%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. has demonstrated promising clinical outcomes for its product candidate RLY-2608, particularly in specific patient populations with kinase mutations, achieving an overall response rate (ORR) of 67% and a median progression-free survival (mPFS) of 11.4 months. The FDA's recent approval of Truqap, which similarly targets advanced breast cancer, underscores the growing recognition and efficacy of therapies that address key biomarker alterations in oncology, further validating Relay’s strategic focus on precision medicine. As the company advances its innovative Dynamo platform and expands its pipeline, the combination of improved clinical data and regulatory support positions Relay Therapeutics favorably for future growth and impact in the biopharmaceutical landscape.

Bears say

Relay Therapeutics is facing significant financial headwinds, with projections indicating a full-year 2025 net loss of $2.15 per share, a slight improvement over the previous year's estimate of $2.36 per share. The company is exposed to multiple risks, including negative clinical data, setbacks in development timelines, and possible failures in obtaining regulatory approvals, which could detrimentally impact its pipeline of drug candidates. Additionally, the competitive landscape poses challenges, with the potential for lower-than-expected commercial success and medium- to long-term dilution risks further complicating the company's financial outlook.

RLAY has been analyzed by 14 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 36% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 14 analysts, RLAY has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.